Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Brain and CNS tumors
MR-Linac adaptive GBM RT shows FLAIR (FHR) omission doesn’t shift failures or survival
UNITED (NCT04726397) is a prospective Phase 2 MR-guided, weekly online-adaptive chemoradiotherapy approach for newly diagnosed glioblastoma using a small GTV-to-CTV margin (CTV=GTV+5mm); clinicians variably extended…
NCT04726397 - Trial result
Colorectal cancer
Prolonging nCRT→TME interval to 12 weeks fails to boost pCR in stage II–III rectal cancer (RCT)
Long-course neoadjuvant chemoradiotherapy (50Gy with concurrent 5-fluorouracil) followed by total mesorectal excision (TME) was tested in an RCT of locally advanced rectal cancer (MRI-staged stage II–III…
NCT03607370 - Trial result
Sarcoma and GIST
DOREMY: 36Gy preop radiotherapy (RT) in myxoid liposarcoma preserves ~97% 5-year local control with low late toxicity
Preoperative RT de-escalation to 36Gy in 18×2Gy followed by resection was tested in the prospective single-arm Phase 2 DOREMY trial in localized, translocation-confirmed myxoid liposarcoma of the trunk/extremity…
NCT02106312 - Trial result
Acute myeloid leukemia and MDS
Ivosidenib (mutant IDH1 inhibitor) + azacitidine drives a 74-month complete remission in IDH1-mutated elderly AML (case report)
Ivosidenib is an oral small-molecule inhibitor of mutant IDH1 used with the hypomethylating agent azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy (IC). In a…
NCT03173248 - Trial result
Other cancers
Preop SBRT (27–30Gy/3fx or 18–24Gy/1fx) before fixation shows 6.5% wound-complication rate in impending metastatic fractures
Preoperative SBRT is an ablative, highly conformal RT technique delivered to gross tumor (rather than a large postoperative bed), here given immediately before orthopedic stabilization to potentially improve local…
NCT05038124 - Trial result
Prostate cancer
NanoKnife focal irreversible electroporation (IRE) shows no new failures at 2 years in intermediate-risk prostate cancer
PRESERVE (NCT04972097) is a prospective, single-arm pivotal FDA IDE study testing focal irreversible electroporation (IRE) with the NanoKnife System—an athermal, high-voltage electrical pulse ablation approach…
NCT04972097 - Trial result Spotlight
Kidney cancer
SABR (26Gy×1 or 42Gy/3fx) Delivers 100% 7-Year Local Control in Inoperable Primary RCC (FASTRACK II)
Stereotactic ablative body radiotherapy (SABR; high-dose, image-guided hypofractionated RT) was tested in FASTRACK II (TROG 15.03), a multicentre, non-randomised Phase 2 study in medically inoperable/high-risk or…
- Trial result Spotlight
Non-small cell lung cancer
CJRB-101 (live Leuconostoc mesenteroides biotherapeutic) + PD-1 blockade drives 58% ORR in PD-L1-high 1L metastatic NSCLC
CJRB-101 is an oral live biotherapeutic product (novel *Leuconostoc mesenteroides* strain) designed to remodel the gut microbiome/tumor microenvironment and was combined with pembrolizumab (anti–PD-1) in a…
NCT05877430 - Trial result Spotlight
Cervical and other gynecologic cancers
T-DXd (HER2 ADC) drives ~45–58% ORR in pretreated HER2-expressing endometrial / cervical / ovarian cancers
Trastuzumab deruxtecan (T-DXd; Enhertu) is a HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, evaluated at 5.4mg/kg in the open-label Phase 2 DESTINY-PanTumor02 study…
NCT04482309 - New trial Spotlight
Multiple myeloma
Phase 2 Linvoseltamab BCMA×CD3 bispecific T‑cell engager vs Isa‑KRd + ASCT in high‑risk NDMM.
MMRC Horizon Two (NCT07053436) is an open-label, randomized, adaptive platform Phase 2 trial in transplant-eligible, high-risk newly diagnosed multiple myeloma with measurable, symptomatic disease. The shared control…
NCT07053436 Exploratory - New trial
Multiple myeloma
Phase 1b sirolimus mTOR inhibitor pre-conditioning plus BCMA×CD3 or GPRC5D×CD3 bispecifics in relapsed/refractory myeloma.
This single-center, single-arm Phase 1b study with an expansion cohort tests whether short-course sirolimus (an mTOR pathway inhibitor that can reshape T-cell activation/exhaustion programs) can “pre-condition” the…
NCT07581704 Exploratory - New trial
Multiple myeloma
Phase 1b/2 selinexor XPO1 (SINE) inhibitor plus carfilzomib proteasome inhibitor in RRMM
This Phase 1b/2, open-label combination study evaluates selinexor (Karyopharm; an oral XPO1/exportin-1 selective inhibitor of nuclear export) with carfilzomib (Amgen; selective, irreversible proteasome inhibitor),…
NCT07479979 Exploratory - New trial Spotlight
Prostate cancer
Phase 1b/2 AZD9574 PARP1 inhibitor + AZD2265 (FPI-2265) PSMA-targeted actinium-225 alpha radioconjugate in mCRPC.
AstraZeneca’s open-label, multi-center platform study in metastatic prostate cancer includes Sub-study 1 for metastatic castration-resistant prostate cancer (mCRPC), testing AZD9574 (a PARP1-selective small-molecule…
NCT07590934 Exploratory - New trial
Prostate cancer
Phase 1b AKY-2519 B7-H3–targeted actinium-225 alpha radiopharmaceutical in mCRPC
Aktis Oncology’s BActinium-1 is a Phase 1b, multicenter, open-label study testing a B7-H3 (CD276)–targeted miniprotein radioconjugate: imaging with [64Cu]Cu-AKY-2519 PET to measure tumor uptake/dosimetry, and therapy…
NCT07581184 Exploratory - New trial
Bladder and urothelial cancer
Phase 1/2 REINFORCE tests enfortumab vedotin Nectin-4 ADC + pembrolizumab PD-1 blockade with consolidation
University of Washington’s Phase 1/2 REINFORCE pilot asks whether patients with unresectable locally advanced, node-positive, or oligometastatic muscle-invasive bladder cancer who achieve a favorable response (CR/PR)…
NCT07579195 Exploratory - New trial
Bladder and urothelial cancer
Phase 2 gemcitabine + Jelmyto mitomycin (DNA crosslinker) chemoablation in high-grade UTUC
Rutgers (Rutgers Cancer Institute of New Jersey) is running this Phase 2, kidney-sparing, single-arm study testing sequential endoluminal gemcitabine and Jelmyto (mitomycin gel) delivered into the affected collecting…
NCT06822010 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 Olanzapine dopamine D2/5-HT2A antagonist to prevent weight loss in gastric cancer
This single-center, randomized, open-label Phase 2 supportive-care study at the University of Illinois Cancer Center (University of Illinois Chicago) tests whether adding low-dose olanzapine (2.5 mg by mouth once…
NCT07581405 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 tislelizumab PD-1 inhibitor plus platinum/fluoropyrimidine chemo in PD-L1+ gastroesophageal cancers.
This open-label, single-arm Phase 2 study sponsored by BeOne Medicines evaluates tislelizumab (a PD-1/CD279–blocking monoclonal antibody designed to restore anti-tumor T-cell activity) combined with standard…
NCT07554521 Exploratory - New trial
Pancreatic cancer
Phase 1 MT-601 multiTAA-specific adoptive T cells target multiple shared tumor antigens.
Marker Therapeutics’ PANACEA Phase 1 dose-escalation with expansion tests MT-601, an autologous (patient-derived) multi–tumor-associated antigen (multiTAA)–specific T-cell product designed to recognize several shared…
NCT06549751 Exploratory - New trial
Pancreatic cancer
N/A NanoKnife irreversible electroporation (cell-membrane nanopore ablation) in unresectable pancreatic cancer
Englewood Hospital and Medical Center is running this single-arm, prospective safety-and-outcomes study evaluating the NanoKnife Irreversible Electroporation (IRE) System used off-label to ablate unresectable…
NCT06937996 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 1/2 navlimetostat PRMT5 inhibitor + pumitamig PD-L1×VEGF-A bispecific in MTAP-loss NSCLC.
This MD Anderson–sponsored Phase 1/2 study tests navlimetostat (aka MRTX1719/BMS-986504), an MTA-cooperative PRMT5 inhibitor designed to preferentially suppress PRMT5 activity in MTAP-deleted tumors, combined with…
NCT07579221 Exploratory - New trial
Breast cancer
Pilot ENDORSE study evaluates response-guided systems medicine report for endocrine-pathway targets (ESR1/PIK3CA/mTOR/HER2)
This pilot, single-arm feasibility study at City of Hope tests whether a biology-guided therapy recommendations report can be delivered on time and be usable in routine decision-making for progressive HR+/HER2-…
NCT07590583 Exploratory - New trial
Breast cancer
Phase 2 NeoTHERa tests HER2 dual-antibody blockade (trastuzumab/pertuzumab) with taxane ± platinum
University of Kansas Medical Center is running this randomized Phase 2 neoadjuvant study in stage II–III HER2-amplified/positive early breast cancer to compare pCR after 6 cycles (every 21 days) of THP vs TCHP before…
NCT07220135 Exploratory - New trial
Breast cancer
Phase 2 inavolisib PI3Kα inhibitor + ribociclib CDK4/6 inhibitor + letrozole in early HR+ breast cancer
This Phase 2, open-label, multicenter neoadjuvant study from Roche/Genentech tests inavolisib-based endocrine combinations in untreated Stage II–IIIC, ER-positive/HER2-negative breast cancer with a tumor PIK3CA…
NCT07054190 Exploratory - New trial
Colorectal cancer
Phase 1 S-adenosylmethionine (SAMe) methyl-donor supplement to modulate epigenetics/microbiome
This first-in-human, single-center, open-label Phase 1 dose-finding study tests daily oral S-adenosylmethionine (SAMe)—the body’s principal methyl-group donor used in cellular methylation reactions—as a potential…
NCT07582003 First-in-human - New trial
Colorectal cancer
Phase 1b DCSZ11 CD93-directed monoclonal antibody adds tumor-vasculature immunotherapy to TNT.
This Johns Hopkins–led Phase 1b, open-label total neoadjuvant therapy study evaluates safety and preliminary activity of DCSZ11 (a CD93-directed monoclonal antibody) combined with short-course radiation plus CAPOX…
NCT07580339 Exploratory - New trial
Kidney cancer
Phase 2 zanzalintinib (XL092) multi-kinase VEGFR2/MET/AXL inhibitor + MO-03 microbiome immunomodulator
This single-arm Phase 2 study at City of Hope tests zanzalintinib (XL092) plus MO-03 (CBM588; *Clostridium butyricum* strain M588) in metastatic clear-cell renal cell carcinoma that has progressed after…
NCT07578025 Exploratory - New trial
Lymphoma
Phase 1/2 golcadomide (CELMoD cereblon E3 ligase modulator) + rituximab (CD20 mAb) in R/R MCL
This Phase 1/2 City of Hope trial evaluates golcadomide plus rituximab for relapsed/refractory mantle cell lymphoma in patients resistant or intolerant to covalent BTK inhibitors. Golcadomide (CC-99282; a Bristol…
NCT07578077 Exploratory - New trial
Lymphoma
Phase 2 nemtabrutinib non-covalent BTK inhibitor plus rituximab anti-CD20 mAb in MZL
City of Hope is running this Phase 2, open-label combination study testing nemtabrutinib + rituximab in patients with marginal zone lymphoma (MZL) who have radiographically measurable nodal or extranodal disease.…
NCT07583810 Exploratory - New trial Spotlight
Lymphoma
Phase 3 PTCL-STAT tests high-dose chemotherapy (DNA-damaging cytotoxic conditioning) + autologous stem cells
This randomized Phase 3 ECOG-ACRIN study (PTCL-STAT; EA4232) asks whether consolidative high-dose chemotherapy followed by autologous stem cell transplant (ASCT) improves outcomes versus observation alone for…
NCT06724237 Registrational
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.